HHS, with the Departments of Labor and Treasury, has issued a new rule to expand the use of health reimbursement coverage, which provide tax-preferred funds for employees to buy their own insurance on the individual market.
Proposed rules to mitigate one of the biggest obstacles to value-based care––interoperability––and provide patients with access to their own health information for free are being met with privacy and security concerns from industry stakeholders.
Brand-name drugs are likely to keep rising in price, even though the top-selling ones have been available for years and have already seen their costs skyrocket, according to a new study published in JAMA.
CMS published its final rule to update the programs of all-inclusive care for the elderly (PACE), which provides comprehensive medical and social services to help keep elderly individuals who qualify for nursing homes in their homes longer.
The Trump administration is expected to release an executive order this week that mandates the disclosure of healthcare prices across the industry, The Wall Street Journal reported. If enacted, the executive order could turn the traditionally opaque healthcare industry on its head.
CMS finalized a rule that aims to boost transparency of the cost of prescription drugs in Medicare Part D and enable Medicare Advantage plans to negotiate better prices for medicines. Notably, the final version backs off a controversial proposal that would have allowed Medicare Part D plans to exclude certain drugs if prices rise beyond a threshold.
As the Trump administration looks for ways to reduce the burden on Americans when they receive a surprise medical bill, it could borrow ideas from New York, which approved legislation in 2014 that has safeguarded residents in the state from being hit with out-of-network charges.
CVS Health is still embroiled in a dispute over its $69 billion merger with Aetna, which was approved by the Department of Justice last year and closed in late 2018. However, U.S. District Judge Richard Leon isn’t so sure the deal hasn’t crossed any antitrust laws and is reviewing the case in court.